Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Sunday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

Check-Cap stock opened at $2.54 on Friday. The firm has a 50 day simple moving average of $2.22 and a 200-day simple moving average of $2.69. Check-Cap has a 1-year low of $1.26 and a 1-year high of $4.63. The stock has a market cap of $14.86 million, a price-to-earnings ratio of -0.84 and a beta of 0.27.

Hedge Funds Weigh In On Check-Cap

A number of hedge funds have recently made changes to their positions in CHEK. Virtu Financial LLC boosted its position in Check-Cap by 363.4% in the 2nd quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock valued at $69,000 after buying an additional 176,207 shares during the period. Citadel Advisors LLC raised its stake in Check-Cap by 51.2% during the 3rd quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock worth $41,000 after acquiring an additional 47,868 shares in the last quarter. Sabby Management LLC acquired a new stake in Check-Cap during the 1st quarter worth $91,000. Susquehanna International Group LLP acquired a new stake in Check-Cap during the 1st quarter worth $57,000. Finally, Nantahala Capital Management LLC acquired a new stake in Check-Cap during the 4th quarter worth $69,000. Hedge funds and other institutional investors own 1.07% of the company’s stock.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.